Comparison
CJC-1295 vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
no data
189691-06-3
Molecular weight
3647.3 g/mol
1025.18 g/mol
Half-life
144 h
2.7 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
5
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
2